Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3921]
News [11368]
Articles [47]
Editorials [10]
Conferences [197]
elearning [4]
ASCEND-8: safety data of ceritinib with or without food in NSCLC
Prof Byoung Chul Cho - Yonsei Cancer Center, Seoul, Republic of Korea
ASCEND-8: safety data of ceritinib with or without food in NSCLC ( Prof Byoung Chul Cho - Yonsei Cancer Center, Seoul, Republic of Korea )
26 Oct 2018
SOLO1: Maintenance olaparib in advanced BRCA ovarian cancer
Dr Kathleen N. Moore - The Stephenson Cancer Center, Oklahoma City, USA
SOLO1: Maintenance olaparib in advanced BRCA ovarian cancer ( Dr Kathleen N. Moore - The Stephenson Cancer Center, Oklahoma City, USA )
26 Oct 2018
Lung highlights from ESMO 2018
Dr Federico Cappuzzo - AUSL della Romagna-Ravenna, Ravenna, Italy
Lung highlights from ESMO 2018 ( Dr Federico Cappuzzo - AUSL della Romagna-Ravenna, Ravenna, Italy )
26 Oct 2018
Erlotinib for neoadjuvant treatment of EGFR NSCLC
Dr Wen-Zhao Zhong - Guangdong General Hospital & Guangdong Academy of Medical...
Erlotinib for neoadjuvant treatment of EGFR NSCLC ( Dr Wen-Zhao Zhong - Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China )
26 Oct 2018
IMpower132: atezolizumab, carboplatin and pemetrexed as first line treatment in...
Dr Fabrice Barlesi - Aix-Marseille University, Marseille, France
IMpower132: atezolizumab, carboplatin and pemetrexed as first line treatment in key subgroups with stage IV non-squamous NSCLC ( Dr Fabrice Barlesi - Aix-Marseille University, Marseille, France )
25 Oct 2018
AURA 3: Mechanisms of osimertinib resistance in patients with EGFR T790M...
Dr Vassiliki A. Papadimitrakopoulou - University of Texas MD Anderson Cancer...
AURA 3: Mechanisms of osimertinib resistance in patients with EGFR T790M advanced NSCLC ( Dr Vassiliki A. Papadimitrakopoulou - University of Texas MD Anderson Cancer Center, Houston, USA )
25 Oct 2018
20 year followup on high-dose chemo with HSCT in high-risk breast cancer
Dr Tessa Steenbruggen - Netherlands Cancer Institute, Amsterdam, Netherlands
20 year followup on high-dose chemo with HSCT in high-risk breast cancer ( Dr Tessa Steenbruggen - Netherlands Cancer Institute, Amsterdam, Netherlands )
25 Oct 2018
Opportunities for biosimilars in practice and education
Prof Diana Lüftner- Humboldt University, Berlin, Germany
Opportunities for biosimilars in practice and education ( Prof Diana Lüftner- Humboldt University, Berlin, Germany )
25 Oct 2018
Comment on the TRIBE-2 study on first and second-line treatment for metastatic...
Dr Filippo Pietrantonio - ‎IRCCS Istituto Nazionale dei Tumori Foundation...
Comment on the TRIBE-2 study on first and second-line treatment for metastatic colorectal cancer ( Dr Filippo Pietrantonio - ‎IRCCS Istituto Nazionale dei Tumori Foundation, Milan, Italy )
25 Oct 2018
VALENTINO: Maintenance therapy in advanced CRC
Dr Filippo Pietrantonio - ‎IRCCS Istituto Nazionale dei Tumori Foundation...
VALENTINO: Maintenance therapy in advanced CRC ( Dr Filippo Pietrantonio - ‎IRCCS Istituto Nazionale dei Tumori Foundation, Milan, Italy )
25 Oct 2018
Pan-cancer assessment of BRCA1/2 genomic alterations by comprehensive genomic...
Dr Neeraj Agarwal - Huntsman Cancer Institute, Salt Lake City, Utah
Pan-cancer assessment of BRCA1/2 genomic alterations by comprehensive genomic profiling of tissue and circulating tumour DNA ( Dr Neeraj Agarwal - Huntsman Cancer Institute, Salt Lake City, Utah )
25 Oct 2018
The Circulating Cell-Free Genome Atlas Study
Dr Minetta C. Liu - Mayo Clinic, Rochester, Minessota
The Circulating Cell-Free Genome Atlas Study ( Dr Minetta C. Liu - Mayo Clinic, Rochester, Minessota )
25 Oct 2018

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation